2025 marks a watershed moment for U.S. healthcare. With the Inflation Reduction Act (IRA) rolling out its next phase, Medicare Part D patients now face a hard $2,000 cap on out-of-pocket drug costs - a move that radically reshapes the pharmaceutical landscape.
For patients, this is a long-overdue relief valve. For manufacturers, it’s a $10B+ liability shift as they now have a mandatory 20% Medicare rebate following a patient reaching the $2,000 out of pocket maximum. And for pharma executives? It’s a call to action.
In 2024, Medicare patients no longer paid 5% coinsurance in the catastrophic coverage phase. That alone effectively capped annual drug spending at $3,300.
The impact was immediate: oncology prescription volumes jumped 50% year-over-year. In 2025, the cap tightens to a flat $2,000, resetting what affordability means for millions.
Make no mistake, this isn’t a temporary spike. We’re witnessing a structural break in how patients behave. Patients who once abandoned scripts due to cost are now starting, staying on, and even adding therapies. As a demonstration of how significant this trend is in oncology, between 2023 and 2024 there was a 15-fold increase in the number of patients who had $0 copays by May.
That’s a win for patients and for public health. But the bill comes due elsewhere.
While patients pay less, pharma and insurers now pay more. Starting in 2025, drugmakers must cover 20% of drug costs in the catastrophic phase—up from 0%. Part D plans take on 60%, up from 15%.
The math gets brutal fast:
For every revenue upside from increased utilization, there’s a reciprocal offset from mandatory discounts. Understanding true net value now requires granular product- and payer-level analysis.
For the Medicare Part D payer, this plays out at an even grander scale. For example, the sum total of increased utilization observed in oncology in 2024 combines with a fourfold increase in liability in 2025. This is not just a few drugs driving greater costs, but the entire branded universe. Broadly, this is estimated to be as high as an incremental $40-50B in liabilities – annually!
Leading pharma companies aren’t sitting still. Here’s how they’re adjusting:
The IRA Part D cap isn’t just a financial event—it’s a behavior transformation. That brings complexity. The industry is being forced to think BIGGER than an individual brand and that stresses manufacturers who do not have enough data to understand anything more than their brand.
And perhaps most crucially: many companies still operate in functional silos, slowing coordination between finance, access, patient services, and policy teams. That’s a recipe for missed opportunities—or worse, strategic missteps. Missing core assumptions on Medicare can not only create forecast inaccuracy but also lead to missed accruals and hundreds of millions of dollars in surprise liabilities.
Pharma companies need to do five things to succeed:
At IQVIA, we’re supporting clients with end-to-end solutions to navigate this complex new landscape:
Most importantly, we’re helping executives act with speed and confidence. In this environment, timeliness is a competitive edge. Do not miss out because you were waiting for your data to see what happened.
Medicare’s $2,000 cap is more than a policy update. It’s a market reset, and may be the most significant near-term consequence of the Inflation Reduction Act. Pharma companies that treat it like a temporary rebate shift will be left behind. Those that engage deeply, with data, empathy, and strategic agility, will unlock new patient growth while preserving margin.
Executives should ask themselves: Are we prepared to lead in this Brave New World? The time to take action is now.
Read this previously published blog to learn about the impact of $0 cost-sharing and future projections for 2025.
Prepare your patient support programs for the Medicare Part D redesign today. Contact IQVIA for expert guidance and tailored solutions to ensure smooth transitions and improved patient outcomes.
Grow your brand, now and through patent expiry
Gain high value access and increase the profitability of your brands